Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Tax Provisions: 2010-2025

Historic Tax Provisions for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $939,000.

  • Anika Therapeutics' Tax Provisions fell 57.32% to $939,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 66.33%. This contributed to the annual value of $6.1 million for FY2024, which is 8.05% down from last year.
  • As of Q3 2025, Anika Therapeutics' Tax Provisions stood at $939,000, which was up 34.14% from $700,000 recorded in Q2 2025.
  • Anika Therapeutics' Tax Provisions' 5-year high stood at $9.1 million during Q4 2023, with a 5-year trough of -$3.4 million in Q4 2021.
  • Its 3-year average for Tax Provisions is $1.3 million, with a median of $700,000 in 2025.
  • Its Tax Provisions has fluctuated over the past 5 years, first crashed by 271.43% in 2022, then surged by 540.00% in 2024.
  • Anika Therapeutics' Tax Provisions (Quarterly) stood at -$3.4 million in 2021, then soared by 293.98% to $6.6 million in 2022, then skyrocketed by 37.62% to $9.1 million in 2023, then slumped by 72.24% to $2.5 million in 2024, then tumbled by 57.32% to $939,000 in 2025.
  • Its Tax Provisions was $939,000 in Q3 2025, compared to $700,000 in Q2 2025 and $100,000 in Q1 2025.